A cost-effectiveness analysis comparing single-inhaler extrafine beclomethasone/formoterol/glycopyrronium bromide against other SITTs in adult patients with uncontrolled asthma in England
BDP/FOR/GLY MS and HS were a dominant treatment alternative compared with FF/UMEC/VI, both MS and HS, and IND/GLY/MF HS in patients with asthma uncontrolled by ICS/LABA.
Authors
- Ioanna Vlachaki (ORCID: https://orcid.org/0000-0002-9306-3750)
- Marielle Van Der Deijl
- Alessandra Madoni (ORCID: https://orcid.org/0009-0005-6794-9127)
- Yuvraj Sharma (ORCID: https://orcid.org/0000-0002-7015-422X)
- Dimitrios Tzelis (ORCID: https://orcid.org/0000-0002-6524-9048)
- I. Guerra
- Simon Donhauser
Institutions
- IQVIA (United Kingdom) (GB)
- Chiesi Foundation (IT)
- Chiesi (Italy) (IT)
- Chiesi (France) (FR)
Publication Details
- Journal
- Health Economics Review
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1186/s13561-025-00640-9
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chiesi Farmaceutici